SUMOylation modulates glucocorticoid-induced muscle toxicity in cell and mouse models

Ahyoung Lee1, Yoonhee Jeong2, Hayeong Kwon3

  • 1Research Institute of Korean Medicine, Pusan National University, 49 Busandaehak-ro, Mulgeum-eup, Yangsan, 50612, Gyeongsangnam-do, Republic of Korea.

Scientific Reports
|July 21, 2026
PubMed

Insights

SUMOylation, a protein modification, protects skeletal muscle from atrophy caused by prolonged glucocorticoid (GC) exposure. Enhancing SUMOylation reduces muscle wasting and preserves function, suggesting it as a therapeutic target for GC-induced muscle toxicity.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Muscle Physiology

Background:

  • Prolonged glucocorticoid (GC) exposure causes skeletal muscle atrophy via glucocorticoid receptor (GR)-dependent catabolic pathways, including Krüppel-like factor 15 (KLF15) activation.
  • Post-translational modifications regulating GC-induced catabolic signaling in muscle are not fully understood.

Purpose of the Study:

  • To investigate the role of SUMOylation as a stress-responsive mechanism in glucocorticoid-induced muscle toxicity.
  • To determine if modulating SUMOylation affects GC-induced skeletal muscle atrophy and catabolic gene expression.

Main Methods:

  • Differentiated C2C12 myotubes and a dexamethasone (DEX)-treated mouse model were used.
  • Pharmacological modulation of SUMOylation using a SUMOylation activator (N106) and a SUMO E1 inhibitor (TAK981).
  • Assessment of morphological, transcriptional, and functional parameters in vitro and in vivo.

Main Results:

  • DEX treatment reduced SUMO-conjugated proteins and induced GR-KLF15-dependent catabolic gene expression.
  • N106 treatment attenuated DEX-induced reductions in myotube diameter and muscle fiber size, and suppressed atrogene induction.
  • N106 mitigated DEX-associated impairments in muscle function (grip strength, endurance); TAK981 enhanced GC-induced catabolic gene expression.

Conclusions:

  • SUMOylation acts as a post-translational regulatory mechanism that limits GR-mediated catabolic transcription during GC stress.
  • Modulating the SUMOylation pathway impacts the severity of GC-induced muscle atrophy, identifying SUMOylation as a key factor in muscle susceptibility to GC toxicity.